Latest filing published 21 Aug 2018 for NEKTAR THERAPEUTICS, €188k.
First 200 filings with a declared amount
Based on 4 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Dennis L. Winger has filed trades across 7 companies (mainly through SEC (Form 4)), most often in Applera Corp, Accuray Inc and Nektar Therapeutics. The record holds 1,596 filings, for trades running from 25 January 2006 to 21 August 2018.
In open-market terms, that means 4 purchases worth €485k on one side and 1,483 sales worth €24.7M on the other. Netting one side against the other leaves €24.2M of net selling. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Other entries cover 37 share grants and 66 option exercises. 2018 to date brings no purchases and 4 sales.
The median purchase comes to €124k. Looking at 4 purchases old enough to measure, the stock rose over the following 90 days in 50% of cases; the median change was -6.9%. Past outcomes like these are no guarantee of what comes next.
Most recently, on 21 August 2018, the filings show an option exercise worth €188k in Nektar Therapeutics. The clock since the last published purchase (8 December 2014) now reads 4,338 days. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 1589 declarations